-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascentage Pharma grants 696,263 RSUs under 2022 incentive scheme

PUBT·04/20/2026 14:33:54
Listen to the news
Ascentage Pharma grants 696,263 RSUs under 2022 incentive scheme
  • Ascentage Pharma Group International granted 696,263 RSUs under 2022 RSU Scheme on April 20, 2026.
  • Grants covered 393,770 RSUs to Yang Dajun, 283,909 RSUs to Zhai Yifan, 18,584 RSUs to a senior manager.
  • Separate award issued 513,192 options under Post IPO Share Option Scheme, split between Yang Dajun and Zhai Yifan.
  • Options carried exercise price of HK$ 51.58 per share; shares closed at HK$ 51.5 on grant date.
  • RSUs represent about 0.19% of issued share capital; options represent about 0.14%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260420-12112906), on April 20, 2026, and is solely responsible for the information contained therein.